New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
09:02 EDTTEVATeva upgraded at Argus
As noted earlier, Argus upgraded Teva to Buy from Hold. The firm upgraded the stock as it thinks the company's prospects have improved following initial steps taken by its new CEO. Target $58.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:07 EDTTEVAFTC, Teva reach $1.2B settlement over Provigil
Subscribe for More Information
08:55 EDTTEVAXenon Pharmaceuticals sees IND for phase 1 trial of XEN801 in mid-2015
Xenon Pharmaceuticals (XENE) announced that Dr. Simon Pimstone, Xenon's President and CEO, will present a business update, including progress toward milestones, at the Jefferies Global Healthcare Conference on Tuesday, June 2. Xenon's partner Teva Pharmaceutical (TEVA) is conducting a randomized, double-blind, placebo-controlled Phase 2b clinical trial for TV-45070 in osteoarthritis. Results from the trial are now expected late in the second quarter or early in the third quarter of 2015. Xenon's partner Genentech, a member of the Roche Group (RHHBY), is currently conducting a Phase 1 clinical trial for GDC-0276, which is expected to complete patient enrollment in the second half of 2015. Xenon expects to file an investigational new drug equivalent application to initiate a Phase 1 clinical trial of XEN801, a stearoyl Co-A desaturase or SCD1 inhibitor for treatment of acne, in mid-2015. If supported by positive data from the Phase 1 trial, Xenon plans to initiate a proof-of-concept Phase 2 clinical trial in the second half of 2015. Xenon expects to file an investigational new drug application for Xenon's Nav1.6 sodium channel inhibitor for Dravet Syndrome in 2016.
06:11 EDTTEVATeva takes 1.35% stake in Mylan, says 'ready to meet' on deal
Subscribe for More Information
May 27, 2015
12:10 EDTTEVATeva to sweeten offer for Mylan before July shareholder vote, NY Post says
Subscribe for More Information
08:24 EDTTEVAFDA reports paragraph IV patent challenge received for Treanda
Subscribe for More Information
May 19, 2015
06:08 EDTTEVAPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 15, 2015
17:08 EDTTEVASoros Fund gives quarterly update on stakes
Subscribe for More Information
09:31 EDTTEVAAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:12 EDTTEVATeva migraine treatment data positive, says Bernstein
Subscribe for More Information
08:04 EDTTEVATeva to present new respiratory data at 2015 ATS conference
Teva Pharmaceutical Industries announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society International Conference in Denver, Colorado on May 15-19.Data to be presented include a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir RespiClick inhalation powder, which gained approval from the U.S. FDA in March 2015. ProAir RespiClick is now available by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. Additional Phase III data to be presented include a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented includes data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler in adolescent and adult patients with asthma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use